Type I error rates of multi-arm multi-stage clinical trials: strong control and impact of intermediate outcomes

BACKGROUND: The multi-arm multi-stage (MAMS) design described by Royston et al. [Stat Med. 2003;22(14):2239–56 and Trials. 2011;12:81] can accelerate treatment evaluation by comparing multiple treatments with a control in a single trial and stopping recruitment to arms not showing sufficient promise...

Descripción completa

Detalles Bibliográficos
Autores principales: Bratton, Daniel J., Parmar, Mahesh K. B., Phillips, Patrick P. J., Choodari-Oskooei, Babak
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Methodology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930581/
https://www.ncbi.nlm.nih.gov/pubmed/27369182
http://dx.doi.org/10.1186/s13063-016-1382-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4930581/
https://www.ncbi.nlm.nih.gov/pubmed/27369182
http://dx.doi.org/10.1186/s13063-016-1382-5

Ejemplares similares